Cencora Inc
NYSE:COR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (51.4), the stock would be worth $503.38 (63% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 31.5 | $308.3 |
0%
|
| 3-Year Average | 51.4 | $503.38 |
+63%
|
| 5-Year Average | 53.1 | $520.03 |
+69%
|
| Industry Average | 3.1 | $30.59 |
-90%
|
| Country Average | 2.5 | $24.63 |
-92%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Cencora Inc
NYSE:COR
|
60B USD | 31.5 | 36.9 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
102B USD | -78.6 | 23.5 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
62.9B USD | 33 | 38.7 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.3B USD | -16.4 | 28.5 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.4B AUD | 6.6 | 35.7 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.1B CNY | 0.8 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 2.8 | 22.7 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.8B CNY | 2.5 | 16.2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 6 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
63.3B HKD | 0.7 | 7.7 | |
| DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
5B EUR | 2.6 | -5.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Cencora Inc
Glance View
Cencora Inc., once known as AmerisourceBergen, stands as a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe. Born from a merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in 2001, the company carved its identity by building extensive networks that bind drug manufacturers, pharmacies, and healthcare providers together into a cohesive chain. This intricate web ensures that pharmaceutical products, ranging from common prescriptions to specialized drugs, reach their destinations efficiently and securely. Cencora's proficiency lies not just in logistics but in its ability to adapt and innovate within rigid regulatory frameworks, ensuring its clients navigate the complexities of compliance while focusing on patient care. In terms of profitability, Cencora thrives on its vast and exponentially growing distribution channels, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods. Moreover, the company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused. Through its multi-faceted business model, Cencora secures its foundation in a volatile industry, supporting the balance of patient needs, market demands, and regulatory compliance.